IRVING, Texas, March 15, 2016 /PRNewswire/ -- Caris Life Sciences®, a leading biotechnology company focused on fulfilling the promise of precision medicine, announced today that the company will present seven poster presentations at the 2016 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancers from March 19-22, 2016 in San Diego, Calif. One of the seven studies, which identified biomarkers implicating drug resistance and alternate treatment options in uterine leiomyosarcomas, was awarded featured poster status.
Each of the studies being presented were conducted in collaboration with leading academic and clinical institutions across the nation, including New York-Presbyterian, Columbia University Medical Center, Weill Cornell Medical College and Fox Chase Cancer Center. The collective set of studies utilized Caris Molecular Intelligence® (CMI), the company's patented and proprietary offering to help physicians make informed therapy decisions, which facilitated biomarker identification and molecular characterization of rare and aggressive gynecologic cancers across different subtypes. The use of CMI enabled investigators to identify the molecular heterogeneity of gynecologic cancers and inform physicians on therapeutic options, including therapies with potential benefit to consider and, just as important, therapies to avoid due to potential lack of benefit.
Following is a schedule of Caris Life Sciences' poster presentations:
Title: | Uterine leiomyosarcomas exhibit distinct drug resistance molecular profiles compared to extrauterine leiomyosarcomas: A comprehensive analysis of 1,023 leiomyosarcomas |
Date and Time: | Sunday March 20, 2016 and Monday, March 21, 2016 from 10:2510:45 a.m. PT |
Abstract #: | 124 |
Location: | Hall B1 |
Session: | Featured Poster Session I |
Authors: | Sudeshna Chatterjee, Joanne Xiu, Sandeep Reddy, Nathaniel Jones, Alexandre Buckley de Meritens, Ana Tergas, William Burke, Jason Wright, June Hou |
Collaborators: | NewYork-Presbyterian Hospital, Columbia University Medical Center, Weill Cornell Medical College, Columbia University College of Physicians and Surgeons |
Title: | Vulvar and vaginal melanoma: A distinct subclass of melanoma based on a comprehensive molecular analysis of 51 cases |
Date and Time: | Sunday March 20, 2016 and Monday, March 21, 2016 from 8:459:05 a.m. PT |
Abstract #: | 257 |
Location: | Hall B1 |
Session: | Poster Session 1 |
Authors: | Caitlin Baptiste, William Burke, Rebecca Feldman, Jason Wright, Ana Tergas, June Hou |
Collaborators: | New York-Presbyterian Hospital, Columbia University Medical Center, Columbia University College of Physicians and Surgeons |
Title: | Identification of molecular targets in vulvar cancers |
Date and Time: | Sunday March 20, 2016 and Monday, March 21, 2016 from 12:2512:45 p.m. PT |
Abstract #: | 271 |
Location: | Hall B1 |
Session: | Poster Session 1 |
Authors: | Premal Thaker, Marguerite Palisoul, Sandeep Reddy, Rebecca Feldman |
Collaborator: | Washington University School of Medicine in St. Louis |
Title: | Multiplatform tumor-profiling of 43 malignant Sertoli-Leydig cell tumors of the ovary reveals therapeutic opportunities |
Date and Time: | Sunday March 20, 2016 and Monday, March 21, 2016 from 2:453:05 p.m. PT |
Abstract #: | 267 |
Location: | Hall B1 |
Session: | Poster Session 1 |
Authors: | Joanne Xiu, Sandeep Reddy, Christina Chu |
Collaborator: | Fox Chase Cancer Center |
Title: | Unique molecular signatures between high-grade and low-grade endometrial stromal sarcoma: An analysis of 96 cases |
Date and Time: | Sunday March 20, 2016 and Monday, March 21, 2016 from 6:457:05 p.m. PT |
Abstract #: | 379 |
Location: | Hall B1 |
Session: | Poster Session 1 |
Authors: | Nathaniel Jones, Joanne Xiu, Sandeep Reddy, Sudeshna Chatterjee, Alexandre Buckley de Meritens, Ana Tergas, William Burke, Jason Wright, June Hou |
Collaborators: | New York-Presbyterian, Columbia University Medical Center, Weill Cornell Medical College, Columbia University College of Physicians and Surgeons |
Title: | Molecular profiling of triple-negative endometrial cancers and triple-negative breast cancers reveals unique expression profiles |
Date and Time: | Sunday, March 20, 2016 and Monday, March 21, 2016 from 7:057:25 p.m. PT |
Abstract #: | 166 |
Location: | Hall B1 |
Session: | Poster Session 1 |
Authors: | Nathaniel Jones, Joanne Xiu, Sandeep Reddy, Sudeshna Chatterjee, Alexandre Buckley de Meritens, Ana Tergas, William Burke, Jason Wright, June Hou |
Collaborators: | New York-Presbyterian, Columbia University Medical Center, Weill Cornell Medical College, Columbia University College of Physicians and Surgeons |
Title: | Molecular profiling reveals distinct molecular landscape in 545 cases of triple-negative endometrial cancer |
Date and Time: | Sunday March 20, 2016 and Monday, March 21, 2016 from 9:4510:05 p.m. PT |
Abstract #: | 167 |
Location: | Hall B1 |
Session: | Poster Session 1 |
Authors: | Nathaniel Jones, Joanne Xiu, Sandeep Reddy, Alexandre Buckley de Meritens, Sudeshna Chatterjee, Ana Tergas, William Burke, Jason Wright, June Hou |
Collaborators: | New York-Presbyterian, Columbia University Medical Center, Weill Cornell Medical College, Columbia University College of Physicians and Surgeons |
About Caris Life Sciences®
Founded by David D. Halbert in 2008, Caris Life Sciences® is a leading biotechnology company focused on fulfilling the promise of precision medicine through quality and innovation. Caris Molecular Intelligence®, the company's patented offering to help physicians make more informed therapy decisions, with more than 85,000 patients profiled, provides oncologists with the most clinically actionable treatment options available to personalize cancer care today. Using a variety of advanced profiling technologies to assess relevant biological changes in each patient's tumor, Caris Molecular Intelligence connects biomarker data generated from a tumor with biomarker-drug associations supported by evidence in the relevant clinical literature through a proprietary bioinformatics rules engine. Since 2009, Caris Life Sciences has tracked clinical and outcome data for certain patients undergoing tumor profiling, and has observed that patients treated with drugs consistent with their tumor profile show a significant increase in overall survival. The company is also developing its ADAPT Biotargeting System, a revolutionary and unbiased profiling platform with applications across therapy development, drug delivery, advanced diagnostics and disease monitoring. Currently being developed for cancer and other complex diseases, the ADAPT Biotargeting System is able to simultaneously measure millions of molecular interactions within complex biological systems in their natural state(s). Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Australia and other international markets. To learn more, please visit www.CarisLifeSciences.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/caris-life-sciences-to-present-molecular-insights-informing-treatment-strategies-at-the-2016-society-of-gynecologic-oncology-annual-meeting-300236068.html
SOURCE Caris Life Sciences
